Back to search
Transplant-Associated Thrombotic Microangiopathy
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Transplant-Associated Thrombotic Microangiopathy trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Transplant-Associated Thrombotic Microangiopathy trials you may qualify forThe goal of this clinical trial is to learn about plasma biomarkers of diagnosed transplant-associated thrombotic microangiopathy (TA-TMA) in patients undergoin…
Thrombotic Microangiopathy (TMA) Associated with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is a serious complication that is associated with inc…
Thymoglobulin is widely applied as serotherapy in order to prevent acute graft-versus-host disease (GvHD) and graft rejection in patients undergoing non-Human L…
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic ste…
The goal of this observational study is to learn about the incidence of Transplant Associated Thrombotich Microangiopathy (TA-TMA), which is a known but underre…
The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients who may benefit from…